The KIAA1191 Knockout SK-HEP-1 Polyclonal Cells consist of a CRISPR/Cas9-edited polyclonal knockout cell population targeting the KIAA1191 gene in the human SK-HEP-1 cell line. This product offers a heterogeneous pool of cells carrying targeted gene disruptions introduced by CRISPR/Cas9-mediated genome editing, providing a loss-of-function model without clonal selection. The polyclonal format preserves population-level genetic diversity, making it suitable for unbiased functional genomics studies.
SK-HEP-1 is an adherent, epithelial human hepatic adenocarcinoma cell line established from the ascites of a 52-year-old male patient. This widely used hepatocellular carcinoma (HCC) model retains oncogenic signaling pathways critical for liver cancer biology, including those governing cell cycle progression and survival. Its well-characterized phenotype and relevance to human disease make it a robust host for gene knockout studies.
KIAA1191 is a poorly characterized protein implicated in cell proliferation control, potentially through ubiquitin-dependent mechanisms. It interacts with the ubiquitin-conjugating enzyme UBE2D1, a component of ubiquitin-mediated proteolysis. This interaction suggests that KIAA1191 may influence the ubiquitination status of downstream cell cycle regulators, thereby modulating proliferation. In the signaling network, KIAA1191 is thought to act downstream of cell cycle signals and upstream of proliferation markers. Disruption of KIAA1191 abolishes its interaction with UBE2D1, perturbing ubiquitin-dependent pathways and allowing functional dissection in HCC.
Knockout of KIAA1191 in SK-HEP-1 cells creates a powerful model to investigate its role in hepatocellular carcinoma proliferation and survival. By comparing the polyclonal knockout population with parental wild-type cells, researchers can identify KIAA1191-dependent phenotypes, such as altered cell growth, cell cycle aberrations, or changes in apoptosis. This model may reveal novel vulnerabilities in HCC, supporting target identification and therapeutic development.
This product is compatible with a variety of downstream assays, including Western blot, RT-qPCR, cell viability, colony formation, flow cytometry for cell cycle and apoptosis, ubiquitination assays, and RNA-seq. Applications range from functional characterization of KIAA1191 and ubiquitination pathway analysis to drug target validation and proliferation studies in liver cancer. For additional information or technical support, please contact Ascent Research.
